Moberg Pharma AB (publ)

Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.